Log in

NASDAQ:HOLX - Hologic Stock Price, Forecast & News

$53.02
+0.58 (+1.11 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$52.26
Now: $53.02
$53.04
50-Day Range
$51.86
MA: $53.27
$54.65
52-Week Range
$42.61
Now: $53.02
$55.25
Volume1.20 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio57.63
Dividend YieldN/A
BetaN/A
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
Current SymbolNASDAQ:HOLX
CUSIP43644010
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6,478
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.


Hologic (NASDAQ:HOLX) Frequently Asked Questions

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) issued its quarterly earnings results on Wednesday, January, 29th. The medical equipment provider reported $0.61 EPS for the quarter, hitting the consensus estimate of $0.61. The medical equipment provider had revenue of $850.50 million for the quarter, compared to analyst estimates of $849.40 million. The firm's quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.58 EPS. View Hologic's Earnings History.

When is Hologic's next earnings date?

Hologic is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Hologic.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its FY20 earnings guidance on Wednesday, January, 29th. The company provided EPS guidance of $2.63-2.67 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.62. The company issued revenue guidance of $3.238-3.268 billion, compared to the consensus revenue estimate of $3.34 billion.

What price target have analysts set for HOLX?

13 brokers have issued 1 year price targets for Hologic's shares. Their forecasts range from $50.00 to $62.00. On average, they expect Hologic's stock price to reach $56.08 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Price Targets for Hologic.

What is the consensus analysts' recommendation for Hologic?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:
  • 1. According to Zacks Investment Research, "Hologic exited the third quarter of fiscal 2019 on a solid note. The company registered strong top-line growth driven by solid increase in core businesses like Breast Health and Molecular Diagnostics. We are also upbeat about the recent launches like Aptima BV and Aptima CV/TV assays in the United States, the Trident HD specimen radiography system in the United States, Europe and Canada, and ThinPrep Genesis processor for cytology slide and molecular test preparation in Europe. Hologic has outperformed its industry over the past three months. On the flip side, foreign exchange headwind got intense during the quarter. Further, both the company’s margins contracted in the quarter under review. This apart volume environment for testing laboratories and utilization weaknesses are looming headwinds." (8/16/2019)
  • 2. Canaccord Genuity analysts commented, "We look for greater evidence for Hologic to find a solution to its declining gross margins and we need more time to get confident that Cynosure has bottomed. Nevertheless, near mid-single-digit growth and effective capital allocation (buybacks and tuck-in deals) are warming us up to the stock as HOLX delivered a 2% top-line beat, 2 cent bottom-line beat, and raised its FY top- and bottom-line guide. That said, its FY’19 raised" revenue is less than the FQ3 $17M beat (FX headwinds being one factor), a consistent trend of setting a low bar for the next reporting quarter and essentially not raising its underlying baseline guide. We reiterate our HOLD, PT to $52. FQ3 beat. (+3.4% rep, +4.7% FXN) exceeded our/Street’s $835ME and adj." (8/1/2019)
  • 3. Needham & Company LLC analysts commented, "FDA’s latest monthly Act (MQSA) statistics were published on 7/1/19. The number of digital breast tomosynthesis (DBT) units increased by 92 during June which represents a 30.8% Y/Y decrease. DBT unit penetration increased to 37.3% from 37.0% last month and facility penetration increased to 62.1% from 61.4% last month. More importantly, DBT units placements were up 2.7% quarter-to-date (QTD) in 2Q19 vs. 2Q18. We note that HOLX’s 3D mammography sales are less than 13% of its total sales. Please contact your Needham salesperson for a copy of our MQSA spreadsheet." (7/10/2019)

Has Hologic been receiving favorable news coverage?

Media coverage about HOLX stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hologic earned a news impact score of 2.0 on InfoTrie's scale. They also gave press coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Hologic.

Are investors shorting Hologic?

Hologic saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 3,630,000 shares, a decrease of 17.1% from the January 15th total of 4,380,000 shares. Based on an average daily trading volume, of 2,335,600 shares, the days-to-cover ratio is presently 1.6 days. Approximately 1.4% of the shares of the company are sold short. View Hologic's Current Options Chain.

Who are some of Hologic's key competitors?

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), salesforce.com (CRM), Starbucks (SBUX), Walt Disney (DIS), Johnson & Johnson (JNJ), Micron Technology (MU) and Bank of America (BAC).

Who are Hologic's key executives?

Hologic's management team includes the folowing people:
  • Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 55)
  • Ms. Karleen M. Oberton, Chief Financial Officer (Age 49)
  • Mr. John M. Griffin, Gen. Counsel (Age 58)
  • Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 56)
  • Mr. Thomas A. West, Division Pres of Diagnostics Solutions (Age 55)

Who are Hologic's major shareholders?

Hologic's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (5.21%), State Street Corp (4.35%), Parnassus Investments CA (2.33%), AJO LP (0.95%), Prudential Financial Inc. (0.89%) and Bank of Montreal Can (0.85%). Company insiders that own Hologic stock include Allison P Bebo, Benjamin Jordan Cohn, Charles J Dockendorff, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Peter J Valenti III, Sally Crawford and Stephen P Macmillan. View Institutional Ownership Trends for Hologic.

Which major investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Mackay Shields LLC, Raymond James & Associates, Laurion Capital Management LP, New York State Common Retirement Fund, Caisse DE Depot ET Placement DU Quebec, Swiss National Bank and ProShare Advisors LLC. Company insiders that have sold Hologic company stock in the last year include Benjamin Jordan Cohn, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Peter J Valenti III, Sally Crawford and Stephen P Macmillan. View Insider Buying and Selling for Hologic.

Which major investors are buying Hologic stock?

HOLX stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Point72 Asset Management L.P., Prudential Financial Inc., Marshall Wace LLP, AJO LP, Assenagon Asset Management S.A., Alyeska Investment Group L.P. and Panagora Asset Management Inc.. View Insider Buying and Selling for Hologic.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $53.02.


MarketBeat Community Rating for Hologic (NASDAQ HOLX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  744 (Vote Outperform)
Underperform Votes:  599 (Vote Underperform)
Total Votes:  1,343
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel